Intercept Pharmaceuticals, Inc. (ICPT): Price and Financial Metrics

Intercept Pharmaceuticals, Inc. (ICPT): $20.28

-0.27 (-1.31%)

POWR Rating

Component Grades













Add ICPT to Watchlist
Sign Up

Industry: Biotech


of 494

in industry

ICPT Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ICPT is -1.87 -- better than just 3.64% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -6.02 for Intercept Pharmaceuticals Inc; that's greater than it is for only 2.66% of US stocks.
  • As for revenue growth, note that ICPT's revenue has grown 24.08% over the past 12 months; that beats the revenue growth of 81.02% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Intercept Pharmaceuticals Inc are LJPC, BNFT, SBBP, AIRG, and PRO.
  • ICPT's SEC filings can be seen here. And to visit Intercept Pharmaceuticals Inc's official web site, go to

ICPT Stock Price Chart Interactive Chart >

Price chart for ICPT

ICPT Price/Volume Stats

Current price $20.28 52-week high $95.98
Prev. close $20.55 52-week low $18.15
Day low $19.82 Volume 5,355,500
Day high $21.50 Avg. volume 1,195,047
50-day MA $24.99 Dividend yield N/A
200-day MA $35.04 Market Cap 669.56M

Intercept Pharmaceuticals, Inc. (ICPT) Company Bio

Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases. The company was founded in 2002 and is based in New York, New York.

ICPT Latest News Stream

Event/Time News Detail
Loading, please wait...

ICPT Latest Social Stream

Loading social stream, please wait...

View Full ICPT Social Stream

Latest ICPT News From Around the Web

Below are the latest news stories about Intercept Pharmaceuticals Inc that investors may wish to consider to help them evaluate ICPT as an investment opportunity.

Intercept (ICPT) Up 0.4% Since Last Earnings Report: Can It Continue?

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | March 27, 2021

Strong Insider Buying Could Indicate a Bottom in These 2 Stocks

Every investor knows that the path toward profits lies in buying low and selling high. That’s a basic precept of any economic trading system. The trick, however, is recognizing when the stock is low enough to buy in. The prime moment to buy is when the stock hits bottom; that will maximize returns when the share price starts to rise again. There are a multitude of possible clues investors can use to find the price bottom; today, we’ll be looking at insider buying trends. Insiders – the corporate officers, board members, and others ‘in the know’ – don’t just manage the companies, they know the details.

Michael Marcus on TipRanks | March 25, 2021

3 Under-the-Radar Growth Stocks With 55% to 106% Upside, According to Wall Street

You've probably never heard about these fast-paced companies before, but Wall Street believes they can make you a boatload of money.

Yahoo | March 15, 2021

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Director Srinivas Akkaraju Acquires 147,000 Shares

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Director Srinivas Akkaraju acquired 147,000 shares of the firm’s stock in a transaction that occurred on Friday, March 12th. The shares were bought at an average cost of $21.29 per share, for a total transaction of $3,129,630.00. Following the purchase, the director now owns 23,121 shares of the company’s stock, valued […]

Watchlist News | March 12, 2021

The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25) Apyx Medical Corp (NASDAQ: APYX ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (announced an $18-million private placement) Bioatla Inc (NASDAQ: BCAB ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Glaukos Corp (NYSE: GKOS ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pacira Biosciences Inc (NASDAQ: PCRX ) (announced fourth-quarter results) Pandion Therapeutics Inc (NASDAQ: PAND ) - announced a deal to be bought by Merck & Co., Inc. (NYSE: MRK ) for $1.85 billion Pliant Therapeutics Inc (NASDAQ: PLRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Down In The Dumps (Biot...

Benzinga | February 26, 2021

Read More 'ICPT' Stories Here

ICPT Price Returns

1-mo -10.66%
3-mo N/A
6-mo -33.25%
1-year -75.05%
3-year -70.71%
5-year -86.44%
YTD -17.89%
2020 -80.07%
2019 22.95%
2018 72.53%
2017 -46.23%
2016 -27.25%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0302 seconds.